Rodman & Renshaw initiated coverage of Rockwell Medical (RMTI) with a Buy rating and $5 price target Rockwell has been a leading provider of dialysis concentrates in the U.S. for over 20 years, supplying essential concentrates used in dialysis machines to help patients with kidney issues, the analyst tells investors in a research note. The firm says that with expected revenue of over $65M in 2025 and potential for further gross margin improvement, the company remains undervalued despite the challenges of heavy customer concentration risk.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on RMTI:
- Rockwell Medical Reports Strong Q3 2024 Earnings
- Rockwell Med Reveals Strategic Corporate Presentation
- Rockwell Medical raises 2024 revenue view to $98.0M-$101.0M from $95.0M-$98.0M
- Rockwell Medical reports Q3 adjusted EPS 9c vs. (4c)
- Options Volatility and Implied Earnings Moves Today, November 11, 2024
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
